GLP-1 RA

Guidelines Obesity Pharmaceuticals

ACP backs GLP-1s first for obesity

Clinical research Diabetes Obesity Pharmaceuticals

Triple hormone receptor agonist improves glycaemic control and bodyweight reduction in T2D

Diabetes Obesity Pharmaceuticals

How do people feel about using GLP-1 RAs?

PBAC Pharmaceuticals

PBAC says yes to tirzepatide for T2D – but Lilly says no

Cosmetic Dermatology Pharmaceuticals

Addressing the cosmetic consequences of medication-induced weight loss